All Posts

by Vista Partners LLC November 18, 2025

Steve Ballmer’s Intuit Dome Unveiled: $2 Billion HQ Redefines Sports Arenas and Corporate Campuses -( $INTU $MSFT $SPY )

Intuit’s (INTU) latest splash isn’t in fintech, but in construction—where the budget now garners more buzz than its balance sheet. Yes, the $2 billion figure making headlines isn’t another buyback authorization or a Silicon Valley campus remodel: It’s the sticker price for the Intuit Dome, the new headquarters fit for a corporate giant—and, coincidentally, a basketball one, too as it is the home of the NBA’s LA Clippers. Depending on one’s taste, the bathrooms may be the crown jewel, or perhaps the “Halo Board” that’s roughly the size of an acre. Either way, Intuit’s ambitions for this project rival its annual revenue, and maybe—just maybe—its penchant for frictionless tax filing.

Construction Costs Fit For an NBA Owner

Emulating the spirit of America’s favorite game show host, Steve Ballmer, Clippers owner and Microsoft’s (MSFT) former head honcho, sunk more than $2 billion into the ‘Dome,’ all in the name of giving fans fewer reasons to miss a three-pointer while waiting in line at a concession stand (or, more urgently, the restroom). With 1,000 restrooms, frictionless checkouts, and 31 kitchens, Intuit Dome seems designed more for bladders than basketballs. If opposing fans ever need consolation, they can at least boast about the LEED-Platinum sustainability rating—one that ensures even the toilet paper is eco-friendly.

The Suite Life: More Than an Office Complex

So what does $2 billion buy these days, besides a few private islands? In this case, it’s a “basketball palazzo” and hybrid campus, sitting on 28 acres adjacent to SoFi Stadium, with a practice facility, offices, and even a dedicated sports medicine wing. Mountain View’s own Intuit campus continues to expand with novel, hybrid-friendly buildings, but Inglewood’s new showpiece brings together much more—concert venues, retail, outdoor plazas, and enough flexible workspaces to keep the average software engineer debating hot-desking etiquette for half a fiscal year.

All-Star Ambitions

Like any tech company worth its cloud servers, Intuit’s new home is future-proofed. The Dome is slated to host the 2026 NBA All-Star Game and likely a few Olympic events in 2028. So if you’re planning your next tax consultation and want decent cell reception, try booking a seat courtside—there might even be a Starbucks in the lobby.

In the end, Intuit’s latest spending spree makes two things clear: the company isn’t afraid to go big (or go home), and its money is now visibly at work—just south of SoFi Stadium, shining almost as brightly as Ballmer’s courtside enthusiasm. Now, if only investors could expense arena concessions at tax time—the true meaning of synergy.

The Sources…

by Vista Partners LLC November 18, 2025

Wall Street Indices Slide as Investors Await Nvidia Earnings – Nov. 17, 2025 -( $EPRX $GOOG $INTG $JAZZ $JNJ $PACS $VIX Rise!)

Monday was a classic “hold your horses” day, with Wall Street digesting fresh economic data, tariff news, and awaiting Nvidia’s AI-focused earnings report later this week. Stock indices retreated modestly but maintain strong YTD performance, investors eyeing the yield curve and FOMC for clues on whether the calm will hold or the market’s next dance is about to begin. Yes indeed, Wall Street opened the week in cautious retreat, as all major U.S. equity indices closed lower on Monday, November 17, 2025. The S&P 500 declined 0.92%, finishing at around 6672.41, pulling back slightly from its strong year-to-date gains of approximately 13.4%. The Dow Jones Industrial Average took the brunt of the selling pressure, dropping 1.18% (about 557 points), closing at 46,590.24 after a previous record close, reflecting a more defensive posture. The Nasdaq Composite mirrored the tech weakness with a 0.84% dip, while the Russell 2000 small-cap index also ended the session in the red down 1.96%, following broader risk-off sentiment. Volatility also rose again today as the market’s ‘fear gauge’ The VIX rose to $22.238, +12.86%. Note that despite the pullback, the indices remain well ahead for the year, with the Nasdaq up about 17.6% and the Dow up 9.5%.

The Macro

Macroeconomic data returned after the longest government shutdown in recent memory, with the Empire State Manufacturing Index surging to 18.7, signaling some strength in the New York manufacturing sector. The U.S. Treasury yield curve stayed inverted, a classic warning sign for the economy, with the 10-year Treasury bond yield hovering around 4.143% and the 2-year at about 3.619%. Markets are now focusing on upcoming jobs reports and the December Federal Open Market Committee (FOMC) meeting, where expectations for interest rates have largely settled on a hold, following a surprise cut in November.

Key Stocks

Among individual stocks, there was little headline-making news. Tech bellwethers including Nvidia, Apple, Alphabet, and Broadcom retreated amid uncertainty ahead of Nvidia’s earnings report scheduled for Wednesday. Nvidia (NVDA) shares have been stellar in 2025, up 38.95% YTD but closed off 1.88% today at $186.60. Alphabet (GOOG), already a $3 trillion market cap company, closed +3.11% higher at $285.60 in the face of the broader tech pullback. Meta, Palantir, and Intel also traded lower alongside the tech sector, while more defensive names like Eli Lilly and McDonald’s saw modest declines. Commodity-linked stocks such as Rio Tinto suffered with weaker metals prices.

Johnson & Johnson (JNJ, $199.58, +1.86%) made headlines with its definitive agreement to acquire Halda Therapeutics, a privately head clinical-stage biotech company famed for its Regulated Induced Proximity Targeting Chimera (RIPTAC) platform, in a $3.05 billion cash deal. The strategic move, set to strengthen J&J’s oncology pipeline—particularly around prostate cancer—underscores Big Pharma’s ongoing fascination with first-in-class modalities and portfolio power-ups.

PACS Group, Inc. (NYSE: PACS, $15.70, +48.39%), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, today announced that it intends to release its third quarter 2025 financial results and file its outstanding annual and quarterly filings through September 30, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on Wednesday, November 19, 2025.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ, $170.09, +20.57%) today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction and esophagus.

Tariffs

On trade policy, the Trump administration made headlines by rolling back tariffs on various food products, including coffee and fertilizers, aimed at easing costs for U.S. consumers and exporters. However, tariffs on steel, aluminum, and automobiles remain, with ongoing negotiations and new trade agreements emerging with Switzerland and Liechtenstein.

Commodities and cryptocurrencies reflected a mixed picture. Gold prices nudged lower by about 0.48%, trading near $4,054.20 per ounce as rate-cut optimism faded. Silver fell nearly 1.15% closer to $50.12 an ounce. Oil prices edged down slightly to $59.69 per barrel after Russian port operations showed signs of normalizing. Meanwhile, Bitcoin underperformed, sliding roughly 2.01% to around $91,932.38, wiping out its gains for the year and highlighting cryptocurrency’s continued volatility.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.5193), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, today (Nov. 17) announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion. On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.60, +.08%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated, “These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.41), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, reported (Nov. 13) its financial results for the quarter ended September 30, 2025, and provided a business update highlighting key corporate and clinical advancements across its vaccine and oncology programs. David Dodd, CEO of Geovax stated, “As highlighted in this report, during the third quarter GeoVax continued making important progress, advancing innovative vaccines and immunotherapies that address urgent and underserved medical needs. With continued global Mpox spread and constrained vaccine supply, our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform. Our EMA and BARDA-aligned program position GeoVax to accelerate regulatory readiness and commercial entry. For our GEO-CM04S1 COVID-19 vaccine program, recent clinical presentations validate our belief that multi-antigen vaccines – expressing both spike and nucleocapsid – are essential for breadth and durability in vulnerable immunocompromised populations. In particular, the robust immune responses demonstrated in Chronic Lymphocytic Leukemia (CLL) patients represents a meaningful step forward in addressing the unmet needs of over 40 million immunocompromised Americans. In our Gedeptin(R) oncology program, the expansion into multiple solid tumor indications builds upon a growing recognition that tumor-targeted immune priming can dramatically improve checkpoint outcomes. We are executing a clear path to clinical and commercial value creation. GeoVax continues to execute with purpose and discipline. Our multi-antigen vaccine and immunotherapy platforms position the Company squarely within the national call to strengthen America’s health security, expand domestic manufacturing, and deliver equitable global solutions.”

Volato Group, Inc. (NYSE American: SOAR, $1.19) and M2i Global, Inc. (MTWO, $.095) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $3.81) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s diseas. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $36.15, +5.58%) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

by Vista Partners LLC November 17, 2025

Blue Origin’s Space Data Centers: The Next Big Leap for AI Infrastructure -( $AMZN $SPY $TSLA )

Blue Origin’s CEO, Dave Limp, has sparked industry attention with his stunningly candid forecast: the world’s biggest AI-optimized data centers will soon decamp from the plains of Utah and the forests of Oregon for the final, distinctly real frontier—outer space. Driven by the crushing energy appetite of artificial intelligence, Limp predicts a future where data centers are launched into Earth orbit, free from terrestrial real estate drama and the ever-present threat of squirrels gnawing on fiber optics.

The Pitch: Humble Bragging from Low Earth Orbit

During a whirlwind media tour, Limp explained with straight-faced optimism that AI’s data-hungry ways might soon overwhelm Earth’s infrastructure. His vision? Massive server farms powered by solar energy, shielded by cosmic radiation, humming contentedly high above the clouds. For all concerned about latency, Limp reassures us: satellites whizzing around at 17,000 mph are a small price to pay for limitless sustainable juice and real estate with a celestial ZIP code.

The Competition: Rockets, Regulation, and Rivalry

The game isn’t limited to Blue Origin. SpaceX, never a company to shy away from orbital one-upmanship, is headlining its own infrastructure ambitions, stoking a new “Silicon Space Race” as each firm vies to make data’s next home address “Cislunar Parkway”. Blue Origin’s recent Mars-satellite deployment and reusable booster landings add real thrust to their bragging rights, making the once-theoretical dream of commercial space platforms appear, dare we say, almost practical.

Not Your Grandpa’s Data Center

Jeff Bezos, having spent the better part of a decade dreaming of gigawatt-scale computing in orbit, echoes Limp’s ambitions, asserting that within ten years the sight of a rocket lofting racks of servers will be as unremarkable as a Tuesday morning earnings call. Data center operators may soon need to update their resumes: “Must be comfortable with zero gravity and able to reboot a server in a pressurized suit.”

Technical Hurdles and Comic Misfires

Skeptics—those with a fondness for gravity—have pointed out challenges involving heat dissipation, cosmic rays, and what happens when a satellite-admin forgets the password and needs to “turn it off and on again” from several hundred kilometers up. Blue Origin’s engineers, presumably fueled by freeze-dried coffee, view these as mere footnotes on their way to a server farm in the stars.

Invest in the Future, Hold the Squirrels

For investors and dreamers alike, Blue Origin’s data center ambitions signal an audacious—if not cosmic—shift in infrastructure thinking. It’s a vision where the cloud is, quite literally, in the clouds. As for the squirrels, they find the whole idea “nuts”—and are happy to stay earthbound.

The Sources…

by Vista Partners LLC November 17, 2025

Modular Medical Gains IRB Green Light for Next-Gen Tubeless Insulin Delivery Device -( $MODD )

Modular Medical (NASDAQ: MODD) is injecting fresh ambition into the world of diabetes care, touting Institutional Review Board (IRB) approval to deliver insulin with its Pivot™ tubeless patch pump to adult study participants just as the company pursues FDA clearance for commercial launch. If wearable medical tech were a fashion runway, the Pivot patch might be the season’s breakout star—but for now, eager endocrinologists and industry observers must wait for that secured FDA stamp before popping any metaphorical champagne.

One Step Closer

Modular’s IRB-sanctioned study will simulate real-world use by test-driving its patch pump with adults using continuous glucose monitors in controlled conditions. The goal is to gather valuable usability metrics, refine device function, and collect feedback from users—after all, optimizing insulin delivery is not quite the same as optimizing a cappuccino machine. CEO Jeb Besser described the IRB milestone as a leap towards market readiness, anticipating that participant data will help refine the user experience after the FDA clearance and potentially supercharge adoption in America’s growing wearable diabetes tech sector.

Pivot Patch: Features and Market Ambitions

Unlike traditional pumps (think spaghetti tubing meets medical device), the Pivot system offers a tubeless experience with a removable 3 ml reservoir and bolus delivery minus a separate controller—an appealing user-friendly touch for those who juggle glucose levels and daily schedules with equal dexterity. By targeting the so-called “almost-pumper” market, Modular Medical is hoping to win patients who want simplicity without sacrificing performance, aiming for a potential slice of the estimated $3 billion pie.

Next Steps: Commercial Dreams (and FDA Realities)

Modular Medical expects initial FDA questions before year-end, with a commercial launch planned for Q1 2026—pending regulatory blessings, of course. As the company polishes the Pivot’s interface for everyday use, investors and patients alike will be watching closely for “usability metrics,” any unexpected hiccups, and, ultimately, that hard-earned FDA clearance. Until then, Modular Medical’s team can savor their IRB victory—perhaps with a glucose-aware donut—while they await the main event.

In Sum:

Modular Medical’s Pivot is believed by management to be on track to shake up diabetes care, provided it can clear a few more regulatory hurdles. And if the patch pump’s approval arrives on schedule, there’s a good chance it’ll be the talk of the medtech town—one patch at a time.

The Sources…

by Vista Partners LLC November 17, 2025

J&J’s $3 Billion Bet: Halda’s Cancer Tech Joins the Pharma Powerball Acquisition Parade -( $JNJ $RNA $NVS $AZN $DIA)

Johnson & Johnson (JNJ) made headlines with its definitive agreement to acquire Halda Therapeutics, a privately head clinical-stage biotech company famed for its Regulated Induced Proximity Targeting Chimera (RIPTAC) platform, in a $3.05 billion cash deal. The strategic move, set to strengthen J&J’s oncology pipeline—particularly around prostate cancer—underscores Big Pharma’s ongoing fascination with first-in-class modalities and portfolio power-ups.

The Halda-J&J Deal: Proximity with Precision

J&J’s bet on Halda’s RIPTAC platform, which offers a novel means to induce targeted cell death in solid tumors, places it at the cusp of next-generation, proximity-based therapies. The acquisition is expected to close in the next few months, pending antitrust clearance—a formality that, in this industry climate, is about as certain as a pharma executive’s fondness for biosimilars. J&J has indicated that while EPS dilution is on the cards for 2026, the long-term commercial prospects have investors seeing more green than a hedge fund Christmas party.

2025’s Biotech M&A Parade

If deal-making in 2025 were a sport, biotech would currently be hosting the Olympics. The year has seen Novartis (NVS) throw $12 billion at Avidity Biosciences (RNA) for an RNA-based neuromuscular disease franchise, while Genmab snapped up Merus N.V. for $8 billion to jazz up its cancer antibody pipeline. Sanofi (SNY) meanwhile, secured Blueprint Medicines for up to $9.5 billion, bolstering its rare disease and oncology reach. Not to be outdone in the cell therapy arms race, Roche (RHHBY) inked a $1.5 billion deal for Poseida Therapeutics and AstraZeneca (AZN) scooped up EsoBiotec and its in vivo CAR-T ambitions for $1 billion.

Healthcare services were not left out of the deal-making dance. Ascension Health’s $3.9 billion acquisition of AMSURG and the Northwell-Nuvance Health merger added tens of billions to operating budgets and substantially reconfigured regional healthcare landscapes.

The Big Picture: Consolidation, Innovation, and a Dash of Hubris

2025’s rush of biotech and healthcare M&A reflects a perfect storm of industry factors: the chase for differentiated assets, a maturing home health and ambulatory care sector, and the eternal quest to outpace the patent cliff with innovative science. As companies like J&J acquire precision tools like Halda’s RIPTAC system, and Novartis, Genmab, and Roche bulk up with new modalities, analysts are running out of synonyms for ‘synergy’ and ‘transformative.’

With Big Pharma on the prowl, clinical scientists are advised to keep their phase 2 data close—and their M&A lawyers closer. After all, in the current market, novel platforms aren’t just a ticket to helping patients, but to billion-dollar courtships and more headlines than a miracle weight-loss drug.

If the tone of M&A this year could be captured in a single phrase, it’s this: “Innovate, acquire, repeat.” As for next year, expect more of the same—unless, of course, antitrust regulators have other ideas.

The Sources…

by Vista Partners LLC November 16, 2025

Opendoor Unveils Special Dividend as Shares Skyrocket: Real Estate Gets a Dose of Silicon Savvy -( $OPEN $SPY $QQQ )

Opendoor Technologies Inc. (NASDAQ: OPEN), the online real estate platform that once made home flipping look like flipping pancakes, has now flipped its script to become an artificial intelligence-driven enterprise, sending its stock soaring nearly 24% ahead of a special dividend announcement. In what might be the finest plot twist on Wall Street this year, Opendoor’s CEO Kaz Nejatian has taken the helm and declared that the company is being “refounded” as a software and AI powerhouse, aiming for profitability by the end of 2026 on a 12-month forward basis.

Despite posting a Q3 revenue of $915 million—down from $1.38 billion the prior year—Opendoor exceeded analyst estimates and laid out an aggressive game plan. Sales volume slowed to 2,568 homes from 3,615 a year ago, yet the company sold more than expected with a sharper focus on quality inventory, all while slashing its legacy home inventories by more than half. Nejatian’s playbook centers on tightening spreads to attract more sellers, accelerating transaction velocity using AI-powered products, and slashing costs through ruthless operational discipline. The company unveiled a novel “Opendoor Checkout” feature promising buyers can tour and bid on homes entirely online, a move that underscores the firm’s AI-first ambitions.

Investors seem to have taken this pivot in stride, rewarded by a remarkable year-to-date stock gain north of 400%, fueled by retail enthusiasm and a wave of optimism about Opendoor’s new direction. The special dividend is a triple warrant offering—basically a shareholder’s version of buying three lottery tickets—granting rights to buy shares at exercise prices between $9 and $17.

JPMorgan’s analyst Dae Lee called the shift “major” and sees the company with the necessary data and scale to disrupt residential real estate, even amid near-term volatility tied to clearing out old inventory and economic uncertainty. Between AI investments, leadership changes, and a fresh product lineup, Opendoor seeks to prove that it’s not just flipping homes, but flipping the entire script on what a tech-savvy real estate platform can be.

Opendoor’s transformation story serves as a reminder to investors: sometimes it pays to bet on a company that dares to disrupt itself before the market forces it to. Only time—and execution—will tell if Opendoor’s AI-driven future will be a slam dunk or a house of cards. For now, Wall Street is bidding at the open house with paper and an irrepressible sense of hope.

Sources

[1] Opendoor Stock Surges Amid Leadership Changes and Strong … https://www.alphaspread.com/market-news/stock-movements/opendoor-stock-surges-amid-leadership-changes-and-strong-market-activity
[2] Opendoor (OPEN) Soars 24% Ahead of Dividends – Insider Monkey https://www.insidermonkey.com/blog/opendoor-open-soars-24-ahead-of-dividends-1646372/
[3] Opendoor Stock Surges Over 21% on Share Buyback Plan and … https://www.tikr.com/blog/opendoor-nasdaq-open-stock-surges-over-21-on-share-buyback-plan-and-analyst-upgrade
[4] Opendoor is an ‘AI company,’ new CEO says. The stock is still falling … https://www.morningstar.com/news/marketwatch/20251106565/opendoor-is-an-ai-company-new-ceo-says-the-stock-is-still-falling-after-earnings
[5] Opendoor Stock Is Climbing Again: Value Trap or Amazing … – Finviz https://finviz.com/news/230982/opendoor-stock-is-climbing-again-value-trap-or-amazing-opportunity
[6] Opendoor (OPEN) Soars 24% Ahead of Dividends – Yahoo Finance https://finance.yahoo.com/news/opendoor-open-soars-24-ahead-161717426.html
[7] Opendoor Stock Is Climbing Again: Value Trap or Amazing … https://www.aol.com/articles/opendoor-stock-climbing-again-value-161100353.html
[8] This CEO Just Made a Big $1 Million Bet on Opendoor Stock https://247wallst.com/investing/2025/11/14/this-ceo-just-made-a-big-1-million-bet-on-opendoor-stock/
[9] Opendoor Q3 2025 Results: $915M Revenue, Net Loss $90M https://www.stocktitan.net/news/OPEN/q3-2025-open-house-opendoor-2-0-charts-path-to-profitability-through-w1uj7yafdsrd.html
[10] Opendoor Stock: Is a Rebound Possible? – StocksToTrade https://stockstotrade.com/news/opendoor-technologies-inc-open-news-2025_11_13/
[11] Massive News: Opendoor Just Announced a Major Pivot – Nasdaq https://www.nasdaq.com/articles/massive-news-opendoor-just-announced-major-pivot
[12] Opendoor Q3 Revenues Beat, Earnings Miss Amid Transition to AI … https://www.zacks.com/stock/news/2788046/opendoor-q3-revenues-beat-earnings-miss-amid-transition-to-ai-model
[13] Opendoor Technologies Inc. (OPEN) Stock Price, News, Quote … https://finance.yahoo.com/quote/OPEN/
[14] Opendoor Technologies Inc (OPEN) Q3 2025 Earnings Call Highlights https://finance.yahoo.com/news/opendoor-technologies-inc-open-q3-030117851.html
[15] What Is Happening With OPEN Stock? – Forbes https://www.forbes.com/sites/greatspeculations/2025/11/13/what-is-happening-with-open-stock/
[16] Earnings call transcript: Opendoor Q3 2025 reveals challenges https://www.investing.com/news/transcripts/earnings-call-transcript-opendoor-q3-2025-reveals-challenges-93CH-4340865
[17] Opendoor Stock – The Comeback Story – Forbes https://www.forbes.com/sites/greatspeculations/2025/11/13/opendoor-stockthe-comeback-story/
[18] Opendoor Technologies Earnings Dates, Upcoming and Historical https://marketchameleon.com/Overview/OPEN/Earnings/Earnings-Dates/
[19] Opendoor Announces Shareholder‑First Dividend of Tradable https://www.globenewswire.com/news-release/2025/11/06/3183243/0/en/Opendoor-Announces-Shareholder-First-Dividend-of-Tradable-Warrants-Aligning-Shareholders-and-Management.html

by Vista Partners LLC November 15, 2025

Merck Mixes Up Its Pipeline With Cidara $9.2B Acquisition—GeoVax Keeps Driving Towards Value in the Vaccine Lane -( $MRK $CDTX $GOVX $IBB )

Merck (MRK), ever the discerning giant of Big Pharma, has decided to join the prophylactic party by acquiring Cidara Therapeutics (CDTX) for a headline-grabbing $9.2 billion—a move that whispers both “strategic pipeline expansion” and “Keytruda’s patent clock is ticking, folks.” In a deal that more than doubled Cidara’s share price overnight, Merck will pay $221.50 per share, an eye-watering 109% premium, and add not just Cidara’s cash-burning potential but also its promising experimental flu drug, CD388, to its infectious disease portfolio.

Merck’s Bet: From Patent Cliff to Flu Cliff

Why toss $9.2 billion into Cidara’s collection plate? Merck is bracing for the revenue cliff as Keytruda, the reigning king of PD-1 inhibitors, closes in on its patent expiry date, while Gardasil faces an increasingly crowded market. Enter CD388, Cidara’s late-phase, long-acting antiviral intended not just for the typical “high-risk” crowd, but potentially broad swaths of healthy adults as well. It’s a shrewd response to a world hungry for pandemic insurance, and Wall Street analysts such as Cantor’s Carter Gould are already forecasting the kind of sales that might help offset incoming patent cliffs.

Notably, Merck couldn’t resist a biotech bidding war rumor, with whispers that at least one rival was eyeing Cidara, proving that even in biopharma M&A, timing is everything—assuming the ability to pay a 100% premium is considered timing and not just bravado.

Meanwhile, at GeoVax: Quietly Advancing the Vaccine Frontier

While Merck and Cidara dance under the M&A limelight, GeoVax Labs (GOVX), that other perennial contender in biotech’s vaccine ring, continues to rack up clinical progress and headline-neutralizing data. GeoVax recently updated the world on its Phase 2 clinical trials for GEO-CM04S1—a next-generation, dual-antigen COVID-19 vaccine aimed at the unusually under-served group of immunocompromised cancer patients. Interim data show not only enhanced T-cell immunity and robust antibody responses in blood cancer and CLL cohorts, but also a safety profile that’s outshining standard mRNA offerings. So impressive, in fact, that the mRNA comparator arm of its CLL trial was axed for futility, leaving GeoVax’s vaccine standing tall.

Never one to leave a regulatory update on the table, GeoVax is also pushing its GEO-MVA vaccine for Mpox and smallpox toward a streamlined Phase 3 clinical trial, skipping the traditional trial phases altogether thanks to recent European regulatory guidance. The company touts a healthy intellectual property portfolio, fresh EMA milestones, and a focus on needle-free, self-administered vaccines via microarray patches. Bioprogress, but with a side of creative delivery.

A Final Word: Old School M&A, New School Science

As Merck and Cidara’s big-dollar deal reminds the sector that megadeals can still get done at double-the-market prices, GeoVax (GOVX) soldiers on in the trenches, one immunogenicity endpoint at a time. Investors—and the science-inclined—can thus enjoy a pharmaceutical market teetering between splashy headlines and the quieter, unflashy progress that sometimes changes the course of global health. In this climate, never underestimate either the power of a corporate checkbook or a well-powered Phase 2 trial.

The Sources…

by Vista Partners LLC November 14, 2025

Wall Street’s Cha-Cha: Shutdowns, Surges, and Market Shenanigans—Weekly Market Wrap, Nov. 14, 2025 -( $AAPL $CDTX $EPRX $LLY $MCD $MODD $MRK $MTWO $NVDA $OPEN $RIO $SER $WHSP Rise!)

If scorekeepers gave points for wit, this week would earn an honorable mention—showcasing the market’s ability to sprint, stumble, and get up again before anyone starts playing the national anthem. Investors, however, are left pondering what comes next, armed with quarterly reports, delayed macro data, and a fresh appreciation for the market’s sense of mischief. Yes indeed as Wall Street’s week came to a close like a well-matured cabernet—complex, a little tart on Thursday’s downswing, but still adding a dash of optimism for those with a taste for macroeconomic uncertainty and tech-sector volatility. For those who prefer their numbers shaken, not stirred, here’s the latest market wrap for the week ending Friday, November 14, 2025.

Equity Index Performance

The S&P 500 eked out a fractional gain, holding onto record territory after a Thursday stumble, and finishing at 6,734.11 for a nearly flat week. The Dow Jones Industrial Average weathered a bumpier ride, slipping 0.7% Friday but still settling up 0.3% for the week, bravely defending its recent foray above 48,000. The Nasdaq Composite, however, couldn’t outpace the high-speed turbulence in tech, ending 0.5% lower for the week—prompting some traders to wonder if artificial intelligence might one day program a less temperamental index. Small caps, represented by the Russell 2000, finished lower as investors donned defensive hats and ducked for cover amid broader risk aversion. but many bids were found on Friday, especially in the biotech sector that swing significantly.

Macroeconomic Reports & US Shutdown Update

Investors hoping for a feast of government economic data found the table a little bare, thanks to the longest shutdown in US history—43 days and counting—a streak that left key figures like CPI, Retail Sales, and the October jobs report languishing in limbo. Private-sector data helped fill the gaps: global manufacturing edged up, though contraction persisted in big economies like Japan and Taiwan, while US consumer debt grew at a 3.1% annual rate and small business optimism inched lower. With shutdowns easing but data delays in the forecast, analysts are bracing for belated government releases, possibly weighed down by more caveats than a Wall Street prospectus.

Company Highlights

Eli Lilly (LLY, $1,025, +10.92% over the last 5-days): The pharmaceutical giant found itself in the buy zone, riding positive sentiment as investor enthusiasm for healthcare stocks continued.
Taiwan Semiconductor Manufacturing (TSMC, $284.82, -.59% over the last 5-days): TSMC kept its chip fabrication running at capacity, with reports of scaling efforts to aid growth-hungry AI players like Nvidia and Tesla.
Nvidia (NVDA, $190.17, +1.07% over the last 5-days): After a Monday rally, Nvidia fell victim to a tech-sector sell-off midweek, as US blocks on certain chip sales to China raised fresh regulatory hurdles.
Apple (AAPL, $272.41, +1.47% over the last 5-days): Apple weathered volatility with little news splash; traders continue to monitor its supply chain and AI investments.
Tesla (TSLA, $404.35, -5.86% over the last 5-days): CEO Elon Musk hinted at a possible “mega AI chip fab” and mused about a possible Intel collaboration, fueling speculation but no signed deals yet.
Broadcom (AVGO, $342.46, -1.99% over the last 5-days): Still riding high on AI optimism, Broadcom seemed to quietly sidestepped the chip-sector noise.
Meta (META, $609.46, -1.97% over last 5-days): Meta got caught in the AI downdraft; its stock declined as investors grew wary of tech valuations.
Nokia (NOK, $6.73,-1.61% over the last 5-days): Nokia kept a lower profile, with its European peers seeing muted action.
McDonald’s (MCD, $307.03, +2.46% over the last 5-days): Digesting steady global sales data, McDonald’s shares remained largely resilient in a defensive sector week.
Rio Tinto (RIO,$70.63, +1.88% over the last 5-days): The miner swept up positive resource news, tracking higher commodity prices.
Oracle (ORCL, $222.85, -6.86% overt he last 5-days): Oracle joined the downward parade with its fellow tech heavyweights, reflecting the sector’s broader malaise, but rebounded a bit on Friday.
Intel (INTC, $35.52, -6.85% over the last 5-days): Potential AI ambitions and chip partnership chatter (thank you, Tesla) kept the rumor mill buzzing, but it nonetheless recoiled significantly this week.
OKLO (OKLO, $97.57, -13.39% over the last 5-days): Low-volume chatter on energy storage startups suggests investors still have an appetite for alternative energy, but OKLO chunked down double digits this week.
Opendoor (OPEN): Shares jumped 23.78% over the last 5-days.
Palantir Technologies (PLTR, $174.20, -2.20% over the last 5-days): Led an AI surge Monday, but saw profit-taking as tech momentum waned.

Mergers, Acquisitions, and Buyouts

Dealmakers found reason to toast: Merck (MRK, $92.92, +7.70% over the last 5-days) acquired Cidara Therapeutics (CDTX, $217.71, +108.55% over the last 5-days) in a $9.2 billion bet on experimental flu prevention, and Lundbeck lobbed a disruptive $2.25 billion bid for Avadel Pharmaceuticals (AVDL, $23.56, +26.06% over the last 5-days). Postman’s API platform vision accelerated with the acquisition of liblab, though most headlines tracked big pharma’s moves as sector standouts.

IPOs

IPOs remained robust, with WeShop Holdings making its direct listing Nasdaq debut under ticker “WSHP,” joining a cohort that has pushed US IPO totals for 2025 nearly 62% higher year-over-year. WHSP share jumped 50.90%. Several filings are still working through delayed data, but overall, the new listing pace remains brisk.

Tariffs and Trade Updates

Tariff talk popped up as AI chip exports to China received fresh restrictions, sparking sales declines at NVIDIA and other tech majors. No new broad-based US import tariff actions were announced this week.

Yield Curve, Interest Rates & FOMC

Bond yields staged a retreat after shutdown resolution, with the 10-year Treasury falling to 4.07% (down 9 basis points), while the 2-year landed at 3.57%. Rate-cut odds for December fell from near-certainty (95%) in October to a coin toss at 50%, courtesy of hawkish Fed remarks and data delays. The next critical FOMC signals and meeting minutes are expected in the coming week, pending data resumption.

Commodities: Gold, Silver, Oil & Bitcoin

Gold staged a volatile show: briefly surging above $4,200/oz before ending at $4,084.40 and stunningly 59.04% higher year-over-year. Silver mirrored these moves, retreating to $50.40/oz, up 65.20% YoY. Oil rebounded to $59.95/bbl, up modestly for the week amid supply hiccups, while OPEC’s 2026 outlook weighed on futures. Bitcoin tumbled below $100,000, trading near $95,266.32 Friday afternoon, suffering in the risk-off sweep that seized equities and crypto markets alike.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.5333, +2.56% over the last 5-days), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.56, +20.37% over the last 5-days), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated, “These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.4511), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, reported (Nov. 13) its financial results for the quarter ended September 30, 2025, and provided a business update highlighting key corporate and clinical advancements across its vaccine and oncology programs. David Dodd, CEO of Geovax stated, “As highlighted in this report, during the third quarter GeoVax continued making important progress, advancing innovative vaccines and immunotherapies that address urgent and underserved medical needs. With continued global Mpox spread and constrained vaccine supply, our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform. Our EMA and BARDA-aligned program position GeoVax to accelerate regulatory readiness and commercial entry. For our GEO-CM04S1 COVID-19 vaccine program, recent clinical presentations validate our belief that multi-antigen vaccines – expressing both spike and nucleocapsid – are essential for breadth and durability in vulnerable immunocompromised populations. In particular, the robust immune responses demonstrated in Chronic Lymphocytic Leukemia (CLL) patients represents a meaningful step forward in addressing the unmet needs of over 40 million immunocompromised Americans. In our Gedeptin(R) oncology program, the expansion into multiple solid tumor indications builds upon a growing recognition that tumor-targeted immune priming can dramatically improve checkpoint outcomes. We are executing a clear path to clinical and commercial value creation. GeoVax continues to execute with purpose and discipline. Our multi-antigen vaccine and immunotherapy platforms position the Company squarely within the national call to strengthen America’s health security, expand domestic manufacturing, and deliver equitable global solutions.”

Volato Group, Inc. (NYSE American: SOAR, $1.35) and M2i Global, Inc. (MTWO, $.10, +.0.00%) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $4.09, +4.60% over the last 5-days ) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s diseas. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $34.24) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

https://finance.yahoo.com/quote/SI=F/history/

https://www.marketwatch.com/livecoverage/stock-market-today-dow-s-p-500-and-nasdaq-set-for-more-selling-bitcoin-trades-below-100-000

https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaqa-nvda-nvidia-stock-tesla-tsla-stock/

https://uk.finance.yahoo.com/news/major-us-stock-indexes-fared-212222093.html

https://www.stl.news/global-markets-turn-defensive-overnight-nov-14-2025/

https://www.youtube.com/watch?v=4x6gZLdVwg4

https://www.reuters.com/business/us-stock-futures-rise-hopes-end-government-shutdown-2025-11-10/

https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-palantir-eli-lilly-buy-zones/

https://www.americanchemistry.com/chemistry-in-america/news-trends/weekly-economic-report/2025/weekly-chemistry-and-economic-trends-11-14-25

https://www.chandlerasset.com/insights/11/14/25-government-shutdown-ends-market-uncertainty-continues?hsLang=en

https://www.cnbc.com/2025/11/14/heres-where-things-stand-on-when-the-government-will-start-releasing-key-economic-reports.html

https://www.cnn.com/2025/11/14/economy/federal-data-what-to-expect-economic-data

https://finance.yahoo.com/news/high-growth-tech-stocks-watch-093826107.html

https://www.nytimes.com/2025/11/14/business/economy-data-shutdown.html

https://www.nasdaq.com/articles/5-top-artificial-intelligence-ai-stocks-buy-november

https://www.reuters.com/legal/litigation/merck-bets-flu-prevention-with-about-92-billion-deal-cidara-therapeutics-2025-11-14/

https://www.businesswire.com/newsroom/subject/merger-acquisition

https://www.fiercepharma.com/pharma/lundbeck-disrupts-alkermes-planned-21b-purchase-avadel-higher-bid

https://stockanalysis.com/actions/acquisitions/2025/

https://www.themiddlemarket.com/latest-news/merck-purchases-cidara-therapeutics-in-9-2b-deal

https://www.biospace.com/business/pfizer-reportedly-planning-to-divest-biontech-stake

https://www.iposcoop.com/ipos-recently-filed/

https://finance.yahoo.com/calendar/ipo/

https://stockanalysis.com/ipos/2025/

https://www.incomeresearch.com/weekly-fixed-income-market-update-november-13-2025/

https://www.federalreserve.gov/releases/h15/

https://www.reuters.com/business/us-10-year-treasury-yields-priced-no-inflation-surprises-set-rise-modestly-2025-11-13/

https://global.morningstar.com/en-nd/markets/december-us-fed-interest-rate-cut-is-now-coin-toss

https://tradingeconomics.com/commodity/gold

https://www.usagold.com/daily-gold-price-history/

https://www.marketwatch.com/investing/future/gcx25

https://www.wsj.com/market-data/quotes/futures/SIX25

https://www.economies.com/crypto/news/bitcoin-tumbles-to-$97,000-amid-a-global-selloff-wave..-whats-happening%20-47749

https://www.usagold.com/daily-silver-price-history/

https://tradingeconomics.com/commodity/crude-oil

https://fortune.com/article/current-price-of-silver-11-14-2025/

https://tradingeconomics.com/commodity/silver

https://www.investing.com/crypto/bitcoin/historical-data

https://finance.yahoo.com/quote/BTC-USD/history/

https://www.forbes.com/advisor/investing/gold-price/

https://www.investopedia.com/dow-jones-today-11122025-11847653

https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-14-2025

https://www.morningstar.com/news/marketwatch/20251114161/wall-streets-on-edge-these-are-the-levels-that-stocks-must-not-violate-says-fundstrat

https://www.jhinvestments.com/weekly-market-recap

https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-14-2025/card/heard-on-the-street-thursday-recap-seeing-red-ho2e3Ow3VPz3mlwwl947

https://www.cnn.com/markets

https://www.benzinga.com/calendars/m-a

https://dealroom.net/blog/upcoming-m-a

https://www.nasdaq.com/market-activity/ipos

https://www.wsj.com/business/deals

https://www.nyse.com/ipo-center/filings

https://www.clevelandfed.org/indicators-and-data/yield-curve-and-predicted-gdp-growth

https://intellizence.com/insights/merger-acquisition/

https://www.isabullion.com/reports/daily-gold-and-silver-market-analysis-14-november-2025/

https://goldprice.org

https://www.dailyforex.com/forex-technical-analysis/2025/11/gold-forecast-14-november-2025/237005

https://finance.yahoo.com/quote/GC=F/history/

https://www.kitco.com/news/article/2025-11-14/gold-market-analysis-november-14-key-intra-day-price-entry-levels-active

https://www.forexfactory.com/news/1371118-gold-price-falls-3-amid-market-selloff

by Vista Partners LLC November 14, 2025

Modular Medical’s Tubeless Insulin Patch Pump Races Toward FDA Review: Can Simplicity Dominate a $3 Billion Market? -( $MODD )

Modular Medical (NASDAQ: MODD) recently ramped up the news cycle with a flurry of regulatory milestones, engineering feats, and even a bit of C-suite global musical chairs—all tailored to make insulin delivery as easy as changing your socks (and almost as affordable).

Modular’s Latest Feats: FDA Race Initiated Post Shutdown

Modular Medical’s engineers just fired the starting gun on the FDA clearance race by submitting their next-generation Pivot tubeless insulin patch pump for 510(k) review as of this morning, November 14, 2025. The device, a “can’t-believe-it’s-not-wearable” patch, sports a 3ml removable reservoir and a detachable design. It seems to be perfect for adults who want to ditch hoses and controllers and finally shower—pump-free—without risking market volatility or their dignity. Jeb Besser, CEO of Modular Medical stated “The Pivot submission is an exciting milestone in our mission to deliver a differentiated tubeless patch pump experience to those who want a simple pump to manage the treatment of diabetes. Our Pivot patch pump offers a 3 ml reservoir, the flexibility of removing the pump and the ability to bolus without a separate controller, all without sacrificing the accuracy, communications and clinical reporting advantages of a true electronic pump. Convincing a person who requires daily insulin to adopt a pump, instead of multiple daily injections, can improve the patient and clinical experience, while potentially reducing healthcare costs and improving long-term patient outcomes. We believe our two-part Pivot patch pump design, easy to learn interface and scalable manufacturing will all contribute to a differentiated user experience and represents a unique approach to this market. On behalf of the board of directors, I would like to thank the entire Modular Medical team, and all of our stakeholders and shareholders for their support to allow us to achieve this major milestone. With the end of the U.S. government shutdown, we have now been able to submit the Pivot for 510(k) clearance to the FDA. We expect to receive initial questions from the FDA this quarter and are proceeding in parallel with the manufacturing preparation to be able to commercially launch our Pivot product upon clearance.”

A Grand Vision, or Just Patchwork?

Not only does Modular Medical claim the Pivot’s design is as simple as a Wall Street bonus structure, it’s going after the “almost-pumpers”—an untapped $3 billion diabetes market segment. The company teases a Q1 2026 commercial launch “upon clearance,” with the necessary disclaimer that FDA reviewers, like Wall Street analysts, are unpredictable.

Production: From Factory Floor to Patient Door

In a manufacturing triumph, Pivot cartridges controller validation was completed. Modular’s team boasted that this milestone “derisks” the path to commercialization. The rigorous process included a Stage 1 ISO 13485:2016 audit with no major nonconformances, an achievement that would make even an SEC examiner smile, or at least raise an eyebrow.

International Moves and Boardroom Shuffles

The company appointed David Bosshard as the new head of international operations, aiming to make Pivot a globe-trotter after charming regulators abroad. Management also touted ongoing progress toward a CE Mark for European entry, planning further audits through 2026. Rumor has it, if the Pivot pump could post on Instagram, it’d be hashtagging “#globalsupplychain”.

Clinical and Real-World Trials: Field-Tested by Docs

MODD’s clinical studies included real-world usage by nine savvy clinicians with Type 1 diabetes. Their feedback is fueling final tweaks before the big Pivot launch. Plus, a new IRB-approved feasibility study is set to test extended wear performance, because even pumps deserve a spa day.

Financing the Future

Behind every headline is a cash register: Modular Medical recently scored gross proceeds of ~$4.4M from the exercise of the Existing Warrants. Investors, clearly believers in patchwork solutions, see the potential to shake up a market used to patchy outcomes.

The Sum…

With diabetes prevalence rising globally, the Company believes it is well positioned to capture significant market share through its innovative patch pump technology. If Modular Medical succeeds, it might just give diabetes care a much-needed injection of simplicity—and the boardroom some reason to break out the (diet) champagne. In the meantime, MODD’s press office is believed to be keeping the insulin (and the news) flowing.

The Sources

by Vista Partners LLC November 14, 2025

Eupraxia Bets on Durable Signals as Pipeline Optionality Grows

In a biotech climate where milestones arrive with the precision of a quarterly forecast and often carry as much suspense as a regulatory ruling, Eupraxia Pharmaceuticals (NASDAQ: EPRX) unveiled (after the close on Nov. 13) new 52-week follow-up data from its RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis. The company framed the update as reinforcing a longer-horizon narrative for its Diffusphere delivery platform, a technology touted as a potential differentiator in a crowded GI space. The message to investors is clear: durability matters as much as peak efficacy, and the long arc of patient outcomes increasingly informs capital allocation decisions.

Data and Implications

The 52-week readout adds to Eupraxia’s storyline around a targeted, local delivery approach designed to improve tolerability and adherence in chronic GI conditions. While headlines focus on durability, analysts will scrutinize endpoints, patient quality-of-life metrics, and safety signals that could justify continued investment in pivotal studies. In a market where a single data point can swing sentiment, Eupraxia’s emphasis on long-term durability signals a strategic preference for therapies that patients can realistically maintain over years rather than months. The company also frames the results as potential indicators of broader pipeline value if the Diffusphere platform translates beyond EoE into other inflammatory indications.

Market Context and Optionality

The EoE landscape remains competitive, with multiple programs racing to demonstrate persistent benefit with acceptable safety profiles. Eupraxia’s narrative hinges on a differentiated delivery technology that could address a key payer and patient concern: long-term convenience and tolerability. By underscoring pipeline optionality, the company suggests that RESOLVE data could support broader development discussions, including potential partnerships or strategic financing to accelerate late-stage programs if the path to pivotal studies encounters delays or regulatory hurdles.

Analyst Perspectives and Financing

Analysts are likely to weigh the durability signals against the overall risk profile typical of early- to mid-stage biotech programs. While positive, the 52-week data must be interpreted within the framework of regulatory timing, trial design considerations, and the economics of delivering a differentiated therapy. Currently analysts have ~$12 price targets for Eupraxia’s stock that closed at $6.34 on Thursday and is up +123.24% over the last year. Furthermore, Eupraxia’s messaging around the platform’s potential to support additional indications could help extend the company’s narrative beyond a single asset, a point of particular interest to investors seeking portfolio leverage in a crowded biotech market. On Nov. 4, Eupraxia confirmed that the Company had cash of $89.0 million as of September 30, 2025, up from $33.1 million at the end of the fourth quarter of 2024. These funds are reportedly being used to fund clinical trials in EP-104 and the remainder of the funds will be used for general and administrative expenses, working capital needs and other general corporate purposes. The Company anticipates that existing cash reserves, and proceeds from the anticipated future exercise of in-the-money warrants, will be sufficient to fund the Company into the first half of 2028.

Strategic Outlook

Looking ahead, Eupraxia’s priorities likely center on refining the clinical development plan for EP-104GI, advancing discussions with potential partners, and outlining a clear path to pivotal trials if the data continue to meet or exceed expectations. The Diffusphere platform could become a central strategic pillar, not only for EP-104GI but possibly for future assets in the pipeline, should the company secure the necessary funding and regulatory clarity to expand its footprint. In the current market, a durable update can serve as a tangible milestone around which management can frame near-term financing conversations and long-run value creation.

Conclusion

In biotech storytelling, promising early data must be tethered to a credible path to market. Eupraxia’s 52-week follow-up data for EP-104GI in EoE reinforces the core thesis: durability matters, and the Diffusphere platform could offer meaningful differentiation in a competitive field. If subsequent trials validate these signals and the company secures the strategic partnerships or financing needed to accelerate development, Eupraxia could move from a narrative of potential to a dated, disciplined plan for value creation in a sector where timelines are as important as the science.

Construction Costs Fit For an NBA Owner

The Suite Life: More Than an Office Complex

All-Star Ambitions

The Sources…

The Macro

Key Stocks

Tariffs

VP Watchlist Updates

The Sources

The Pitch: Humble Bragging from Low Earth Orbit

The Competition: Rockets, Regulation, and Rivalry

Not Your Grandpa’s Data Center

Technical Hurdles and Comic Misfires

Invest in the Future, Hold the Squirrels

The Sources…

One Step Closer

Pivot Patch: Features and Market Ambitions

Next Steps: Commercial Dreams (and FDA Realities)

In Sum:

The Sources…

The Halda-J&J Deal: Proximity with Precision

2025’s Biotech M&A Parade

The Big Picture: Consolidation, Innovation, and a Dash of Hubris

The Sources…

Sources

Merck’s Bet: From Patent Cliff to Flu Cliff

Meanwhile, at GeoVax: Quietly Advancing the Vaccine Frontier

A Final Word: Old School M&A, New School Science

The Sources…

Equity Index Performance

Macroeconomic Reports & US Shutdown Update

Company Highlights

Mergers, Acquisitions, and Buyouts

IPOs

Tariffs and Trade Updates

Yield Curve, Interest Rates & FOMC

Commodities: Gold, Silver, Oil & Bitcoin

VP Watchlist Updates

The Sources

Modular’s Latest Feats: FDA Race Initiated Post Shutdown

A Grand Vision, or Just Patchwork?

Production: From Factory Floor to Patient Door

International Moves and Boardroom Shuffles

Clinical and Real-World Trials: Field-Tested by Docs

Financing the Future

The Sum…

The Sources

Data and Implications

Market Context and Optionality

Analyst Perspectives and Financing

Strategic Outlook

Conclusion

The Sources

Your Guide To Staying Informed In The Markets